- G02 -

First of its kind Alzheimers Head to Head Study Comparing Leading Biomarkers Closes Unprecedented participation from underrepresented communities Menu Speeding up the delivery of Alzheimers Parkinsons Disease Treatments GAP and our over 100 clinical research partners GAPNet Sites around the world are collaborating to speed the delivery of Alzheimers and Parkinsons disease treatments with a commitment to promoting diversity in clinical research as well as lowering the cost and duration of clinical trials to ensure that no one is left behind. Nearly 7 Million Americans are currently living with Alzheimers disease. 141 Increase in deaths from Alzheimers between 2000 and 2021. 360 Billion The estimated cost of treating Alzheimers in the United States in 2024.